Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국
일요일, 8월 23

Revolution Medicines Inc

RVMDNASDAQ
Trade with Public
Trade with Public
$209.46
-2.28-1.07%
가까이에: Aug 21, 5:00 PM EST
$209.50
0.040.02%
시간외: Aug 21, 7:50 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Revolution Medicines Analyst Price Targets

Wall Street analyst price targets and consensus rating for Revolution Medicines (RVMD).

Price Target Range — 8 Quarters

Analyst Consensus — 21 Analysts

1S.Buy
19Buy
1Hold
Consensus RatingBuy# Analysts21Avg. Consensus PT$146Upside to Avg. PT-30.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 21, 2026BernsteinJeffrey WalchPT RaiseMarket Perform$151→$179
Aug 11, 2026Truist SecuritiesGregory RenzaPT RaiseBuy$210→$231
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Bernstein Maintains Market Perform on Revolution Medicines, Raises Price Target to $179

Bernstein analyst Jeffrey Walch maintains Revolution Medicines (NASDAQ:RVMD) with a Market Perform and raises the price target from $151 to $179.
Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $231

Truist Securities analyst Gregory Renza maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $210 to $231.
Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $203

RBC Capital analyst Leonid Timashev maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $182 to $203.
Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Revolution Medicines, Raises Price Target to $201

Wedbush analyst Robert Driscoll maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $192.1 to $201.
Benzinga Newsdesk

PRO
Evercore ISI Group Maintains Outperform on Revolution Medicines, Raises Price Target to $230

Evercore ISI Group analyst Cory Kasimov maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $220 to $230.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Revolution Medicines, Raises Price Target to $240

Guggenheim analyst Michael Schmidt maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $235 to $240.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

Benzinga

Benzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved